|Articles|July 1, 2005

Pharmacy Times

  • Volume 0
  • 0

Osteoporosis Drug May Prevent Memory Loss

Author(s)Susan Farley

In a study of the drug raloxifene (Evista), researchers at the San Francisco VA Medical Center found that, while the drug helps prevent osteoporosis in women, it also may help prevent age-related memory loss. More than 7700 women participated in the study, taking 60 or 120 mg of raloxifene or placebo for 3 years. In addition to preventing osteoporosis, the drug has been used to treat breast cancer, acting like estrogen in some tissues and like antiestrogen in others. Although scientists have been unable to determine how raloxifene affects memory, they found that those taking the 120-mg dose had a 33% lower risk of developing mild cognitive impairment, compared with those taking the 60-mg dose or placebo. They also noticed a slight reduction in the risk of Alzheimer's disease.

Ms. Farley is a freelance medical writer based in Wakefield, RI.

Articles in this issue

over 20 years ago

Calcium: An Essential Mineral

over 20 years ago

CAN YOU READTHESE Rxs?

over 20 years ago

ECKEL RECEIVES ALUMNI AWARD

over 20 years ago

Cancer: Update on Biologics

over 20 years ago

PHARMACIST'S RIGHT TO CHOOSE?

over 20 years ago

Teenage Drug Diversion—Part 2

over 20 years ago

Is Altering Refills a Criminal Act?

over 20 years ago

Do All SSRIs Interact the Same Way?

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.


Latest CME